

IN THE MATTER OF	*	BEFORE THE
AMANDA ROLES, PHARM TECH	*	STATE BOARD
Registration No.: T15126	*	OF
Respondent	*	PHARMACY
	*	Case No. PT-15-012

* * * * *

ORDER FOR SUMMARY SUSPENSION

Pursuant to Md. State Govt (SG) Code Ann. §10-226 (c) (2) (2014 Repl. Vol. II), the State Board of Pharmacy (the "Board") hereby suspends the registration to practice as a Pharmacy Technician (Pharm Tech) in Maryland issued to **AMANDA ROLES**, (the "Respondent"), under the Maryland Pharmacy Act (the "Act"), Md. Health Occ. (H.O.) Code Ann. §§ 12-101 *et seq.*, (2014 Repl. Vol. II.). This Order is based on the following investigative findings, which the Board has reason to believe are true:

INVESTIGATIVE FINDINGS

1. At all times relevant hereto, the Respondent was registered to practice as a Pharm Tech in Maryland. The Respondent was first registered on September 3, 2014. The Respondent's registration expires on October 31, 2015.
2. At all times relevant hereto, the Respondent was employed as a Pharm Tech at a National chain pharmacy in Annapolis, Maryland, hereinafter "Pharmacy A."
3. By letter dated November 20, 2014, Pharmacy A notified the Board of a significant loss or theft of Controlled Dangerous Substances (CDS) enclosing a copy of

a Drug Enforcement Administration (DEA) "Report of Theft of Loss of Controlled Substances",

4. The DEA form listed the following :

Clonazepam ¹ , 1 mg	30 tablets;
Clonazepam, 2mg	105 tablets;
Valium ² , 10 mg	4 tablets;
Alprazolam ³ , 2 mg	700 tablets
Oxycodone HCL ⁴ , 20 mg	100 tablets.

5. Pharmacy A also submitted a summary of its investigation which occurred as follows:

- A. On or about October 22, 2014, Pharmacy A's Regional Loss Personnel Manager (RLPM) was called to Pharmacy A after being advised by the Store Manager that the Respondent was in the Store Manager's office because the Respondent was caught leaving Pharmacy A with a bottle of Oxycodone 20 mg;
- B. The RLPM also determined that the pharmacist had received the CDS into the store from the supplier and allowed the Respondent to scan them in;

¹ Clonazepam treats seizures, panic disorder, and anxiety.

² Valium is the trade name for diazepam, which treats anxiety, muscle spasms, seizures, and other medical conditions. This medicine is a benzodiazepine.

³ Alprazolam treats anxiety and panic disorder.

⁴ Oxycodone HCl Controlled-Release Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time.

C. When the Respondent asked to go on a break in the midst of checking in the CDS, the pharmacist's suspicions were aroused and he immediately paged her to come back to the pharmacy, where she was asked to remove her smock;

D. Upon the removal, the pharmacist noticed a bulge in her clothing, which he questioned whereupon which the Respondent removed the bottle and started to cry;

E. The Respondent stated that she had "anxiety issues" and had removed "a couple of pills" from the pharmacy—namely Clonazepam, 1 and 2 mgs;

F. The Respondent also admitted taking drugs from two other stores in the pharmacy chain;

G. In addition to the oral admissions, the Respondent signed a statement admitting to the thefts and she also signed a promissory note to repay Pharmacy A for the stolen merchandise.

6. As a result of the above, the Respondent was terminated from employment.

7. As a result of the above, the police were called and they arrested the Respondent.

8. The Respondent was criminally charged in the District Court of Maryland for Anne Arundel County with the following:

Count 1

CDS Poss—Not Marijuana;

Count 2

Theft, less \$1000.

CONCLUSIONS OF LAW

Based on the foregoing, the Board finds that the public health, safety or welfare imperatively requires emergency action, pursuant to S.G. §10-226 (c) (2).

ORDER

Based on the foregoing, it is therefore this 16th day of March, 2015, by a majority vote of a quorum of the State Board of Pharmacy, by authority granted to the Board by SG. §10-226 (c) (2), the registration held by the Respondent to practice as a Pharm Tech in Maryland, Registration No. T15126, is hereby **SUMMARILY SUSPENDED**; and be it further

ORDERED that, upon the Board's receipt of a written request from the Respondent, a Show Cause Hearing shall be scheduled within a reasonable time of said request, at which the Respondent will be given an opportunity to be heard as to whether the Summary Suspension should be continued, regarding the Respondent's fitness to practice as a Pharm Tech and the danger to the public; and be it further

ORDERED, that the Respondent shall immediately turn over to the Board her wall certificate and wallet-sized registration to practice as a Pharm Tech issued by the Board; and be it further

ORDERED that this document constitutes a final Order of the Board and is, therefore, a public document for purposes of public disclosure, as required by Md. Code Ann. General Provisions §§4-101 *et seq.* (2014 Vol.).



Laverne G. Naesea, Executive Director
Board of Pharmacy

NOTICE OF HEARING

A Show Cause hearing to determine whether the Summary Suspension shall be continued will be held before the Board at 4201 Patterson Avenue, Baltimore, 21215 following a written request by the Respondent for same.